Chief Investigator: Dr Mitchell Lawlor
The Glaucoma Registry was officially launched during RANZCO 2017 in Perth Australia.
Given the total annual health care cost to Australia of Glaucoma is expected to increase to $4.3 billion by 2017, it is crucial to determine effective and safe treatments to improve patient’s outcomes and minimize the burden of this disease.
It is currently unknown whether certain interventions are effective, feasible and safe in routine practice or long term.
The best way to answer these and other questions is via our FGB system developed to facilitate post marketing surveillance of the treatments for glaucoma. We will study whether results achieved in clinical trials can be replicated in routine practice, whether the new treatments improve quality of life, how they are best administered and whether they are safe. Success in this project will benefit patients, doctors, government agencies, other health care providers and industry.
In a similar way to other Registries under the SSR umbrella, a sophisticated interface also allows clinicians to capture patient’s response on the perceived effect of treatment on their quality of life. This is done simply by the patient entering their responses directly into an iPAD® or any hand-held device. The responses once submitted are then automatically and securely transmitted to the database.
For more information – Click here
Contact: Email us on email@example.com